PerkinElmer (NYSE: PKI) and EnteroMedics (NASDAQ:RSLS) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Valuation and Earnings

This table compares PerkinElmer and EnteroMedics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
PerkinElmer $2.14 billion 3.69 $416.05 million $3.31 21.63
EnteroMedics N/A N/A N/A ($16.72) -0.11

PerkinElmer has higher revenue and earnings than EnteroMedics. EnteroMedics is trading at a lower price-to-earnings ratio than PerkinElmer, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

PerkinElmer has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, EnteroMedics has a beta of 3.07, indicating that its stock price is 207% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for PerkinElmer and EnteroMedics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PerkinElmer 2 8 5 0 2.20
EnteroMedics 0 0 1 0 3.00

PerkinElmer presently has a consensus target price of $67.69, indicating a potential downside of 5.47%. EnteroMedics has a consensus target price of $11.03, indicating a potential upside of 486.70%. Given EnteroMedics’ stronger consensus rating and higher possible upside, analysts plainly believe EnteroMedics is more favorable than PerkinElmer.


This table compares PerkinElmer and EnteroMedics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PerkinElmer 16.80% 13.44% 6.85%
EnteroMedics -7,350.29% -98.09% -85.43%

Insider and Institutional Ownership

92.1% of PerkinElmer shares are owned by institutional investors. Comparatively, 0.9% of EnteroMedics shares are owned by institutional investors. 2.2% of PerkinElmer shares are owned by company insiders. Comparatively, 32.5% of EnteroMedics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. EnteroMedics does not pay a dividend. PerkinElmer pays out 8.5% of its earnings in the form of a dividend.


PerkinElmer beats EnteroMedics on 8 of the 13 factors compared between the two stocks.

PerkinElmer Company Profile

PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.

EnteroMedics Company Profile

ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with's FREE daily email newsletter.